Copeptin - is There a Role for Another Cardiac Biomarker?
The discovery and development of new biomarkers continues to be a promising field. Since cardiovascular disease remains the principal cause of death in the developed countries, this is the area in which novel biomarkers have been most extensively evaluated. Arginine vasopressin (AVP or antidiuretic hormone) is one of the key hormones in the human body involved in cardiovascular homeostasis. It has so far escaped introduction into the routine clinical laboratory due to technical difficulties and pre-analytical errors. Copeptin, the C-terminal part of the AVP precursor peptide, was found to be a stable and sensitive surrogate marker for AVP release. During the past years, copeptin measurement has been shown to be of interest in a variety of clinical indications, including cardiovascular diseases such as heart failure, myocardial infarction, and stroke. This review summarizes the recent progress in the diagnostic use of plasma copeptin in cardiovascular diseases.
Pencina MJ, D'Agostino RB, Vasan RS. Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med 2010; 48(12): 1703-11.
Hochholzer W, Morrow DA, Giugliano RP. Novel biomarkers in cardiovascular disease: Update 2010. Am Heart J 2010; 160(4): 583-94.
Chan D, Leong LN. Biomarkers in acute myocardial infarction. BMC Medicine 2010: 8: 34.
Morrow DA, De Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007; 115: 949-52.
Chrmandari E, Tsigos C, Chrousos G. Endocrinology of the stress response. Annu Rev Physiol 2005; 67: 259-84.
Chrousos G, Gold PW. The concepts of stress and stress system disorder. Overview of physical and behavioral homeostasis. JAMA 1992; 267(9): 1244-52.
Volpi S, Rabadan-Diehl C, Aguilera G. Vasopressinergic regulation of the hypotalamic pituitary adrenal axis and stress adaptation. Stress 2004; 7(2): 75-83.
Katan M, Christ-Crain M. The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med Wkly 2010; 140: w13101.
Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the Measurement of Copeptin, a Stable Peptide Derived from the Precursor of Vasopressin. Clin Chem 2006; 52(1): 112-9.
Seligman R, Papassotiriou J, Morgenthaler NG, Meisner M, Teixeira PJZ. Copeptin, a novel prognostic biomarker in ventilator-associated pneumonia. Crit Care 2008; 12(1): R11.
Stoiser B, Mörtl D, Hülsmann M, Berger R, Struck J, Morgenthaler NG, Bergmann A, Pacher R. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 2006; 36(11): 771-8.
Khan SQ, Dhillon SO, O'Brien RJ, Struck J, Quinn PA, Morgenthaler NG, Squire IB, Davies JE, Bergmann A, Leong L. Terminal Provasopressin (Copeptin) as a Novel and Prognostic Marker in Acute Myocardial Infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) Study. Circulation 2007; 115; 2103-10.
Katan M, Müller B, Christ-Crain M. Copeptin: a new and promising diagnostic and prognostic marker. Crit Care 2008; 12(2): 117.
Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides 2005; 26(12): 2500-4.
Müller B, Morgenthaler NG, Stolz D, Schuetz P, Müller C, Bingisser R, Bergmann A, Tamm M, Christ-Crain M. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 2007; 37(2): 145-52.
Christ-Crain M, Opal SM. Clinical Review: The role of biomarkers in the diagnosis and management of community acquired pneumonia. Crit Care 2010; 14(1): 203.
Katan M, Fluri F, Morgenthaler NG, Schuetz P, Zweifel C, Bingisser R, Müller K, Meckel S, Gass A, Kappos L, Steck AJ, Engelter ST, Müller B, Christ-Crain M. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol 2009; 66(6): 799-808.
Zweifel C, Katan M, Schuetz P, Siegemund M, Morgenthaler NG, Merlo A, Mueller B, Christ-Crain M. Copeptin is associated with mortality and outcome in patients with acute intracerebral hemorrhage. BMC Neurology 2010: 10: 34.
Barreca T, Gandolfo C, Corsini G, Del Sette M, Cataldi A, Rolandi E, Franceschini R. Evaluation of the secretory pattern of plasma arginine vasopressin in stroke patients. Cerebrovasc Dis 2001; 11(2): 113-18.
Reichlin T, et al. Incremental Value of Copeptin for Rapid Rule Out of Acute Myocardial Infarction. J Am Coll Cardiol 2009; 54: 60-8.
Neuhold et al. Comparison of Copeptin, B-Type Natriuretic Peptide, and Amino-Terminal Pro-B-Type Natriuretic Peptide in Patients With Chronic Heart Failure. J Am Coll Cardiol 2008; 52(4): 266-72.
Voors AA, Von Haehling S, Anker SD, Hillegel HL, Struck J, Hartmann O, Bergmann A, Squire I, Van Veldhuisen DJ, Dickstein K. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J 2009; 30(10): 1187-94.
Morgenthaler NG. Copeptin: a biomarker of cardiovascular and renal function. Congest Heart Fail 2010; 16(1): S37-44.
Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, et al. Use of Multiple Biomarkers to Improve the Prediction of Death from Cardiovascular Causes. N Engl J Med 2008; 358: 2107-16.
Christ-Crain M, Stolz D, Jutla S, Couppis O, Muller C, Bingisser R, Schuetz P, Tamm M, Edwards R, Muller B, Grossman AB. Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia. Am J Respir Crit Care Med 2007; 176: 913-20.
Katan M, Morgenthaler NG, Widmer I, Puder J, König C, Müller B, Christ-Crain M. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett 2008; 29(3): 341-6.
Robertson GL. The use of vasopressin assays in physiology and pathophysiology. Semin Nephrol 1994; 14: 368-83.
Morales DL, Garrido MJ, Madigan JD, Helman DN, Faber J, Williams MR, Landry DW, Oz MC. A double-blind randomized trial: prophylactic vasopressin reduces hypotension after cardiopulmonary bypass. Ann Thorac Surg 2003; 75: 926-30.
Mellander O, et al. Novel and Conventional Biomarkers for Prediction of Incident Cardiovascular Events in the Community. JAMA 2009; 302(1): 49-57.